-
平臺編號：bio-68281
-
國際編號：CRL-2515?
-
細(xì)胞信息： CL3
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
CL3
生長狀態(tài)：懸浮生長
ATCC Number：CRL-2515?
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來源：小鼠
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
規(guī)格：0.1ml Designations: CL3
Depositors: ?C Smith
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E.
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with human umbilical vein endothelial cells (HUVEC) that had been stimulated with recombinant interleukin-1 (IL-1).
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
The antibody reacts with human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E.
The antibody reacts, immunohistochemically, with rat pulmonary endothelial cells pretreated with tumor necrosis factor alpha (TNF-alpha). [47313 ]
Antibody produced by CL3 (ATCC CRL-2515 ), but not CL37 (ATCC CRL-2516 ), blocks in vitro adherence of neutrophils to TNF alpha-treated endothelial cells and the killing of TNF alpha-treated rat endothelial cells by phorbol ester activated neutrophils. [47313 ]
The antibody protects against IgG immune complex-induced rat lung injury by reducing neutrophil accumulation.
It inhibits neutrophil binding to IL-1 stimulated HUVEC. [47312 ]
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 47312: Kishimoto TK, et al. Antibodies against human neutrophil LECAM-1 (LAM-1/Leu-8/DREG-56antigen) and endothelial cell ELAM-1 inhibit a common CD18-independent adhesion pathway in vitro. Blood 78: 805-811, 1991. PubMed: 1713515
47313: Mulligan MS, et al. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J. Clin. Invest. 88: 1396-1406, 1991. PubMed: 1717513
ATCC Number：CRL-2515?
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來源：小鼠
運(yùn)輸方式：凍存運(yùn)輸
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
規(guī)格：0.1ml Designations: CL3
Depositors: ?C Smith
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E.
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with human umbilical vein endothelial cells (HUVEC) that had been stimulated with recombinant interleukin-1 (IL-1).
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
The antibody reacts with human E-selectin (endothelial leukocyte adhesion molecule 1 (ELAM-1)); CD62E.
The antibody reacts, immunohistochemically, with rat pulmonary endothelial cells pretreated with tumor necrosis factor alpha (TNF-alpha). [47313 ]
Antibody produced by CL3 (ATCC CRL-2515 ), but not CL37 (ATCC CRL-2516 ), blocks in vitro adherence of neutrophils to TNF alpha-treated endothelial cells and the killing of TNF alpha-treated rat endothelial cells by phorbol ester activated neutrophils. [47313 ]
The antibody protects against IgG immune complex-induced rat lung injury by reducing neutrophil accumulation.
It inhibits neutrophil binding to IL-1 stimulated HUVEC. [47312 ]
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 47312: Kishimoto TK, et al. Antibodies against human neutrophil LECAM-1 (LAM-1/Leu-8/DREG-56antigen) and endothelial cell ELAM-1 inhibit a common CD18-independent adhesion pathway in vitro. Blood 78: 805-811, 1991. PubMed: 1713515
47313: Mulligan MS, et al. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J. Clin. Invest. 88: 1396-1406, 1991. PubMed: 1717513
